Merck & Co Inc said told a scientific meeting in San Diego that its candidate immunotherapy for house dust mite allergy showed a significant dose-and time-dependent reduction in a nasal symptom score. The therapy is called MK-8237. ---Subscribe to MedNous to access this article--- Clinical Research Company News
